WT
AXDX icon

Washington Trust’s Accelerate Diagnostics AXDX Stock Holding History

Washington Trust’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-265
Closed -$59K – 276
2018
Q2 		$59K Buy
+265
New +$59.3K ﹤0.01% 389

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
AAMU
Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

Washington Trust's AXDX Position: Q3 2018 in Review

Washington Trust sold out of Accelerate Diagnostics (AXDX) in Q3 2018, closing a stake of 265 shares — an estimated $59K sold.

Washington Trust first reported a position in AXDX in Q2 2018 and held it in 1 quarter. The position peaked at $59K in Q2 2018. 118 funds tracked by Wall St. Rank hold AXDX as of Q3 2018.

  • Washington Trust reported no remaining Accelerate Diagnostics position as of Q3 2018 after selling out during the quarter.
  • Washington Trust sold 265 Accelerate Diagnostics shares in Q3 2018, an estimated $59K.
  • Washington Trust first reported a position in Accelerate Diagnostics in Q2 2018 and held it in 1 quarter.
  • Washington Trust's Accelerate Diagnostics position peaked at $59K in Q2 2018.
  • 118 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2018.

Based on Washington Trust's 13F filing for Q3 2018, filed 13 Nov 2018.